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of sixteen countries from the region according to different criteria: characteristics, 
quality (using Drummond’s checklist), use of local data, addressed inputs limita-
tion and results transferability. Results: Economic evaluations are used in CEE 
countries for informing decision making, while critically considering methodology, 
quality and study’s reliability. Experts acknowledged limited generalizability of study 
results both between and within geographic regions. Meanwhile, despite these con-
straints, facing limited health technology assessment (HTA) capacity experts were 
still using foreign evidence. At the same time, the usefulness of studies published in 
CEE and former Soviet countries to inform their decision making is limited because 
of insufficient transparency in reporting, unaddressed uncertainty, limited insight on 
inputs and transferability of results. Although local costs, baseline risk and resource 
use data are required, experts accept evidence originating from health care settings 
outside CEE and former Soviet countries regarding relative effect and utilities val-
ues. ConClusions: HTA priority setting and transferability assessment of economic 
evidence are important issue in health care decision making in CEE and former Soviet 
countries, since HTA research capacity is limited and local evidence is scarce. For this 
purpose, quality, transparency, and transferability should be addressed explicitly in 
published economic evaluations originating from CEE and former Soviet countries.
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BACkgRound: The Department of Science and Technology (DECIT) at the Ministry 
of Health (MoH), since 2003, has financed studies to support demands from 
the MoH technical areas regarding the decision making process about health 
technologies. oBjeCtives: To analyze DECIT performance in financed Health 
Technology Assessment (HTA) studies to improve the capacity building of HTA in 
Brazil. Methods: A retrospective descriptive study based on the analysis of docu-
ments and official records built in a single database in Excel containing the studies 
promoted by DECIT from 2003 to November 27, 2013. The variables pre-classified 
and collected from Brazilian Network for Health Technology Assessment’s database, 
SISREBRATS, were revised by two reviewers and conferred or supplemented with data 
from the Database of Health Research, Annual Reports Management by DECIT, and 
Final Reports and Cooperation Agreements by co-financier partners. Results: 284 
HTA projects were financed entirety for R$ 25 million (± R$ 1,69 million) between 2003 
and 2013. The average value financed was R$ 346 thousand and the average bias was 
± RS 61 thousand. Of these, 57% (162/284) are pharmacotherapy; and 35% (99/248) are 
systematic reviews. The majority of the studies 58% (165/284) were financed by MoH 
calls in years 2005 to 2010 and contributed to 110 masters and doctors conclusions in 
HTA landfield. ConClusions: These numbers show despite the HTA culture in Brazil 
having been in its initial stage, DECIT is increasing its capacity to respond to demands 
with a variety of studies types, specily in pharmacotherapy. However, evaluation 
demands do not always correspond to health needs of promotion and prevention.
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oBjeCtives: Since January 2011, pharmaceutical manufacturers are obliged to sub-
mit dossiers presenting benefits over comparative treatment when launching new 
products in the German pharmaceutical market. These dossiers are usually evalu-
ated by the Institute for Quality and Efficiency in Health Care (IQWiG). Based on the 
dossier, the IQWiG’s evaluation and a subsequent hearing process, the Federal Joint 
Committee (G-BA) decides on additional therapeutic benefit related to mortality, 
morbidity, quality of life (QoL) and side effects. As QoL is among the more contested 
of these criteria and remains comparably unspecified, this qualitative study’s aim 
was to analyze definitions and the role of QoL in early assessments of benefit (EAB) 
in Germany. Methods: As most of the documents are freely available on the G-BA’s 
website, this study included all relevant documents of the first completed 66 assess-
ments (11.2011-12.2013). We conducted a qualitative content analysis screening the 
dossiers, IQWiG evaluations, G-BA decisions and the protocols of the oral hearing for 
relevant links to QoL and synonyms. In a process of independent analysis and joint 
consensus building by two researchers, relevant text passages were extracted and 
reduced to key content on the term’s usage. During analysis, a system of codes was 
developed accounting for a wide variety of recurring QoL-related definitions and 
references to its importance. Results: Even though key players did not necessarily 
share the same QoL-definition, the concept’s relative importance was highlighted in 
numerous references. G-BA decisions criticize the lack of or the inadequate presen-
tation of QoL data in the manufacturer’s dossiers. G-BA and IQWiG apply a narrow 
understanding of QoL, while manufacturers failed to establish wider notions of QoL 
linking factors such as patient satisfaction to the concept. ConClusions: QoL in a 
particular sense is of pivotal importance in Germany’s early assessment of benefit. 
The demand for reliable QoL data is growing.
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oBjeCtives: Advanced-therapy medicinal products (ATMPs), such as gene therapy, 
cell therapy and tissue engineering are a new class of medicines in the EU. ATMPs 
offer prospects in prevention and treatment of fatal and/or chronic debilitating 
diseases where no effective treatments exist. However, with complicated mecha-
nisms of actions and benefits often being anticipated in the longer term, it is chal-
lenging to demonstrate hard clinical evidence and create robust cost-effectiveness 
models that Payers have come to expect at the launch of pharmaceuticals. Thus, 
manufacturers face difficulties when negotiating the price for ATMPs and may not 
be able to realize their full potential. This paper aims to use case studies of ATMPs 
launched in EU5 to outline access pathways and review the clinical and economic 
evidence requirements. Methods: Secondary research identified ATMP approv-
als since 2008 and a framework was created to develop hypotheses on clinical 
and economic evidence requirements, considering alternative routes to market. 
Hypotheses were then validated during in-depth interviews with key stakeholders 
across EU5. Results: Payers are yet to be convinced about the full benefit of ATMPs 
and are reluctant to pay premium prices if they are not sure about long-term effi-
cacy and safety. Additionally, in their cost-benefit analyses, Payers tend to consider 
only the direct costs associated with a condition, ignoring broader societal benefits 
and savings in the long run. Therefore, price negotiations are sometimes lengthy. 
Risk sharing and novel payment-by-result schemes are often agreed to mitigate 
risks. ConClusions: Payers are not yet familiar with the potential value of ATMPs, 
and, in most cases specific evaluation criteria don’t exist. Manufacturers need to 
invest in educating Payers on the huge differences between ATMPs and traditional 
therapies, particularly to show that manufacturing costs are substantial, and work 
together to identify relevant measures for clinical and economic evaluations of 
this new therapy class.
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oBjeCtives: The Objectives are to present the characteristics of the quick-HTA 
started in June 2013 and to show the Results of the first quick-HTA process in 
Romania. Methods: The health care context and the Romanian legislation cov-
ering HTA were studied by considering: the reasons behind HTA introduction, the 
key stakeholders and the HTA process. A critical appraisal was done covering public 
HTA reports and the decisions taken by the Ministry of Health (MofH). Results: 
The introduction of quick-HTA began mid-June 2013 when MofH released the leg-
islation and the HTA Unit started receiving dossiers for new drugs/indications. The 
HTA model was based on a “score-card” system with 6 criteria: HAS (France) opinion, 
NICE/SMC/AWMSG (UK) opinion, the number of EU countries with reimbursement, 
relative efficacy, relative safety and relative patient-reported-outcomes (PRO), but no 
role of budget impact. From June to December 2013, 167 HTA dossiers were evaluated 
by the HTA Unit with an acceptance rate of about 80%. Most of the drugs accepted for 
reimbursement were oncological (23%); other main therapeutic areas were diabetes 
with 16 drugs/indications receiving positive evaluations, rheumatology (14), onco-
haematology (8) and neurology (7). The HTA included also biosimilars, all 4 of them 
receiving positive decisions. Unfortunately, early 2014, the new Government abrogated 
this HTA legislation and the already-published HTA reports, claiming that the process 
didn’t mentioned the criteria for de-listing reimbursed drugs nor the budget impact, 
within HTA reports. Moreover, the HTA process was moved into the responsibility of 
the National Agency for Drugs. ConClusions: The implementation of the quick-HTA 
in Romania took a good start, using a mixture of information, from benefits and cost-
effectiveness in other countries, to relative effectiveness, safety and PRO. However, 
the lack of consideration for the local context and the political disagreements led to 
a temporary suspension of this quick-HTA process in Romania.
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oBjeCtives: The objective of the study was to provide an external assessment 
of recent HTA institutionalization in Brazil, and identify a set of lessons learned 
potentially applicable to BRICS States. Methods: This research is based on a quan-
titative and qualitative assessment. A literature survey between 2000 and 2014 was 
conducted in English, Spanish and Portuguese in PubMed/Medline, Science Direct, 
LILACS and SciELO. Epidemiological and socio-economic data was retrieved from 
national health accounts as well as WHO/PAHO, OECD and World Bank. For the 
Brazilian National Committee for Incorporation of Technologies (CONITEC), avail-
able reports on the incorporation of medicines into the National Unified System 
(SUS) for the first two years of operation (2012 and 2013) were analyzed. A matrix 
containing quantitative and qualitative criteria was elaborated to analyze reports 
by the outcome of decision, therapeutic class, author (s) of the request and public 
consultation. Results: A total of 92 available CONITEC reports for 2012 (n= 38, 33 
for medicines) and 2013 (n= 54, 42 for medicines) were analyzed. 45% of reports on 
medicines recommended incorporation into the SUS. Most of the positive recom-
mendations were clearly related to public health priorities as identified by the gov-
ernment, translating a strong commitment for improved access to medicines within 
the SUS i.e. anti-cancer drugs. Overall, the creation of the CONITEC represents a 
substantial step toward the institutionalization of HTA, with more transparency 
and accountability in decision-making processes, considering ethical, organiza-
tional, social, and legal aspects. ConClusions: Whereas lowest in Russia, India 
and South Africa, and at a transitional stage in China, Brazil has a comparable 
degree of institutionalization of HTA as countries with a long-lasting HTA experi-
ence. A best-practice assessment in the area of HTA within the BRICS has still to be 
elaborated. Transferability of lessons learned might be a strong tool for improving 
HTA development within the BRICS.
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